Guselkumab (Tremfya) — coverage criteria for IV and SC administration
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, site-of-care, dosing limits, and documentation requirements for guselkumab (Tremfya) IV and SC administration across FDA-approved indications (psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease); affects prescribers, infusion centers, and prior authorization reviewers.
Allowance added for patients currently established on a biologic or systemic immunomodulator agent for the requested indication who have had positive clinical benefit from that agent.
For CD and UC, removed required trial/failure of conventional therapy and replaced with requirement to demonstrate moderately to severely active disease using symptoms plus objective evidence of active inflammation or other specified criteria.
Expanded pediatric eligibility for PS and PsA to patients >=6 years who weigh at least 40 kg and updated UC induction dosing to include IV or SC options per FDA label.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.